Vislyfa (ranibizumab biosimilar) / Lupin - LARVOL DELTA

Positive recommendations on new biosimilar medicine (European Medicines Agency) - "The treatment of neovascular (wet) age-related macular degeneration (AMD); The treatment of visual impairment due to diabetic macular oedema (DME) - The treatment of proliferative diabetic retinopathy (PDR); The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO); The treatment of visual impairment due to choroidal neovascularisation (CNV)."

CHMP • Diabetic Macular Edema • Diabetic Retinopathy • Retinal Vein Occlusion • Wet Age-related Macular Degeneration